Kiromic Biopharma, Inc. financial data

Symbol
KRBP on OTC
Industry
Biological Products, (No Diagnostic Substances)
Location
7707 Fannin St., Suite 140, Houston, Texas
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Kiromic, Inc. (to 11/15/2019)
Latest financial report
Q1 2024 - May 10, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 27.2 % -11%
Debt-to-equity -294 % +90.8%
Return On Equity 322 % -95.4%
Return On Assets -166 % +27%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.29M shares +31.6%
Common Stock, Shares, Outstanding 1.29M shares +31.6%
Entity Public Float 3.18M USD -52.8%
Common Stock, Value, Issued 1K USD +2.15%
Weighted Average Number of Shares Outstanding, Basic 1.3M shares +49.5%
Weighted Average Number of Shares Outstanding, Diluted 1.3M shares +49.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 10.6M USD -19.1%
General and Administrative Expense 9.7M USD -37.2%
Operating Income (Loss) -20.3M USD +28.9%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -21.8M USD +33.3%
Earnings Per Share, Basic -7.42 USD/shares +86.8%
Earnings Per Share, Diluted -7.42 USD/shares +86.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.68M USD +78.9%
Assets, Current 5.57M USD +58.3%
Property, Plant and Equipment, Net 5.65M USD -25.5%
Operating Lease, Right-of-Use Asset 1.39M USD -30.1%
Goodwill 0 USD
Other Assets, Noncurrent 21K USD -13.9%
Assets 12.6M USD -3.66%
Accounts Payable, Current 2M USD -75.5%
Employee-related Liabilities, Current 946K USD +1402%
Liabilities, Current 19.1M USD -3.86%
Operating Lease, Liability, Noncurrent 747K USD -46.2%
Liabilities 19.8M USD -6.63%
Retained Earnings (Accumulated Deficit) -129M USD -20.3%
Stockholders' Equity Attributable to Parent -7.21M USD +11.4%
Liabilities and Equity 12.6M USD -3.66%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.7M USD -38.1%
Net Cash Provided by (Used in) Financing Activities 6.19M USD +11.8%
Net Cash Provided by (Used in) Investing Activities -21K USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 1.29M shares +31.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 472K USD -66.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.68M USD +79%
Interest Paid, Excluding Capitalized Interest, Operating Activities 5K USD -61.5%
Deferred Tax Assets, Valuation Allowance 22.5M USD +15%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 22.8M USD +14.1%
Operating Lease, Liability 1.39M USD -30.1%
Depreciation 2.22M USD +8.58%
Payments to Acquire Property, Plant, and Equipment 21K USD
Lessee, Operating Lease, Liability, to be Paid 1.51M USD -32.2%
Property, Plant and Equipment, Gross 11.1M USD +2.68%
Operating Lease, Liability, Current 642K USD +7.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 243K USD -66.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 725K USD +1.03%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 117K USD -50.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 243K USD -66.5%
Deferred Tax Assets, Operating Loss Carryforwards 16.2M USD +27.7%
Preferred Stock, Shares Issued 22K shares
Preferred Stock, Shares Authorized 60M shares
Lessee, Operating Lease, Liability, to be Paid, Year Four 243K USD
Additional Paid in Capital 122M USD +22.9%
Preferred Stock, Shares Outstanding 22K shares
Share-based Payment Arrangement, Expense 18.2K USD
Interest Expense 167K USD +1265%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares